Effects of Qingyi decoction combined with ulinastatin on the recovery of intestinal function and levels of inflammatory factors in patients with acute pancreatitis

doi:10.3877/cma.j.issn.2095-2015.2024.03.014

Abstract

Abstract:

Objective

To evaluate the effects of Qingyi decoction combined with ulinastatin on the recovery of intestinal function and the levels of inflammatory factors in patients with acute pancreatitis.

Methods

From May 2020 to May 2023, 111 patients with acute pancreatitis who visited Taihe County People's Hospital were selected, and 90 patients with acute pancreatitis were finally included as the study objects. Using a random alphabetical list, patients were divided into a control group (n=45) and an observation group (n=45). Both groups underwent conventional treatment, the control group received ulinastatin, while the observation group was treated with Qingyi decoction in addition to ulinastatin. Traditional Chinese Medicine symptom scores, clinical efficacy, recovery of intestinal function (time to return of bowel sounds, time to first flatus, time to first stool), levels of inflammatory factors (TNF-α, IL-1β, IL-6, PAF, MCP-1), and adverse reactions were compared between the two groups.

Results

After treatment, the total effective rate in the observation group was 95.56%, significantly higher than the 77.78% in the control group (P<0.05). Symptom scores for chest tightness, abdominal pain, body heat, thirst, nausea, vomiting, heaviness of the head and body, and unsatisfactory defecation, which are evaluated based on Traditional Chinese Medicine criteria, decreased in both groups after treatment. Moreover, scores in the observation group were notably lower than those in the control group (P<0.05). The recovery of intestinal function in the observation group was significantly superior to the control group (P<0.05). Both groups demonstrated a marked decrease in inflammatory factors post-treatment, and the levels in the observation group were significantly lower than those in the control group (P<0.01). The incidence of adverse reactions in the observation group was significantly lower than that in control group (P<0.05).

Conclusion

The clinical effect of Qingyi decoction and ulinastatin is more significant than that of ulinastatin alone in the treatment of acute pancreatitis. It can further shorten the time for intestinal function recovery, alleviate inflammation, and reduce the incidence of adverse reactions.

Key words: Acute pancreatitis, Qingyi decoction, Ulinastatin, Clinical efficacy, Intestinal function, Inflammatory factors

Qinghua Xu, Zhenlin Zhang, Hao Li. Effects of Qingyi decoction combined with ulinastatin on the recovery of intestinal function and levels of inflammatory factors in patients with acute pancreatitis[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 253-257.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.03.014

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I03/253

Figures/Tables 6

References 31

[1]	马德渊, 李山林, 李艳秋. 生长抑素乌司他汀联合氧化苦参碱对重症胰腺炎肠粘膜屏障损伤的改善及HMGB1水平的影响[J]. 河北医学, 2020, 26(11): 1877-1881.
[2]	孙衍模, 陈书德, 许声江. 乌司他丁、生长抑素联合奥曲肽治疗急性胰腺炎的临床研究[J]. 中国临床药理学杂志, 2019, 35(23): 3021-3024.
[3]	Szatmary P, Grammatikopoulos T, Cai W, et al. Acute Pancreatitis: Diagnosis and Treatment[J]. Drugs, 2022, 82(12): 1251-1276.
[4]	Petrov MS, Yadav D. Global epidemiology and holistic prevention of pancreatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 175-184.
[5]	Garg PK, Singh VP. Organ Failure Due to Systemic Injury in Acute Pancreatitis[J]. Gastroenterology, 2019, 156(7): 2008-2023.
[6]	裴亮, 周平, 张俊勇. 乌司他汀对急性胰腺炎患者抗氧化能力及炎症反应的影响[J]. 当代医学, 2021, 27(32): 141-143.
[7]	陈紫兰, 巫苏晓. 清胰汤联合乌司他丁治疗重症急性胰腺炎的疗效及其对患者免疫功能的影响[J]. 天津中医药, 2023, 40(3): 291-296.
[8]	怀昆, 梁国强, 章一凡, 等. 任氏清胰汤治疗轻中度急性胰腺炎的临床效果[J]. 中国当代医药, 2024, 31(3): 137-142.
[9]	项红, 王治洲, 尚东. 清胰汤治疗急性胰腺炎的作用及分子药理机制[J]. 时珍国医国药, 2018, 29(2): 408-411.
[10]	Wei TF, Zhao L, Huang P, et al. Qing-Yi Decoction in the Treatment of Acute Pancreatitis: An Integrated Approach Based on Chemical Profile, Network Pharmacology, Molecular Docking and Experimental Evaluation[J]. Front Pharmacol, 2021, 12: 590994.
[11]	Wang G, Shang D, Zhang G, et al. Effects of QingYi decoction on inflammatory markers in patients with acute pancreatitis: A meta-analysis[J]. Phytomedicine, 2022, 95: 153738.
[12]	中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 浙江实用医学, 2021, 26(6): 511-519, 535.
[13]	张声生, 李慧臻. 急性胰腺炎中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志, 2017, 33(11): 2052-2057.
[14]	van den Berg FF, Boermeester MA. Update on the management of acute pancreatitis[J]. Curr Opin Crit Care, 2023, 29(2): 145-151.
[15]	丁平, 王选举. 生长抑素与乌司他丁联合肠内营养治疗重症急性胰腺炎患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(1): 10-13.
[16]	叶浩, 彭余胜, 冯淑涵, 等. 通腑清胰汤治疗急性胰腺炎疗效及对患者中医证候积分与肠功能的影响[J]. 陕西中医, 2021, 42(4): 474-477.
[17]	孟灿, 黄婷婷, 李从燕, 等. 清胰汤治疗急性胰腺炎临床疗效和对炎症因子水平的影响研究[J]. 河北中医, 2023, 45(2): 249-252.
[18]	Boxhoorn L, Voermans RP, Bouwense SA, et al. Acute pancreatitis [J]. Lancet, 2020, 396(10252): 726-734.
[19]	Bansal A, Gupta P, Singh H, et al. Gastrointestinal complications in acute and chronic pancreatitis[J]. JGH Open, 2019, 3(6): 450-455.
[20]	Ashraf H, Colombo JP, Marcucci V, et al. A Clinical Overview of Acute and Chronic Pancreatitis: The Medical and Surgical Management[J]. Cureus, 2021, 13(11): e19764.
[21]	Meng L, Wu Z, Zhang H. Effect of Ulinastatin Combined with Octreotide on Serum Endothelin, Endotoxin Levels and Immune Function in Acute Pancreatitis[J]. J Coll Physicians Surg Pak, 2019, 29(1): 90-92.
[22]	Liu R, Qi H, Wang J, et al. Ulinastatin activates the renin-angiotensin system to ameliorate the pathophysiology of severe acute pancreatitis[J]. J Gastroenterol Hepatol, 2014, 29(6): 1328-1337.
[23]	朱卫东. 清胰汤联合常规西药治疗急性胰腺炎临床研究[J]. 河南中医, 2022, 42(5): 727-730.
[24]	楼炎灵. 清胰汤对急性胰腺炎患者急性时相反应蛋白及胰腺血流、功能的影响观察[J]. 中国医学创新, 2023, 20(4): 107-111.
[25]	沈正艳. 清胰汤加减保留灌肠联合西医常规治疗肝郁气滞型急性胰腺炎43例[J]. 中医研究, 2021, 34(1): 32-34.
[26]	赵春梅, 彭美霞, 姚小燕, 等. 清胰汤和雷火灸改善急性胰腺炎患者胃肠动力障碍的效果比较[J]. 护理学杂志, 2021, 36(8): 29-30, 72.
[27]	王晶晶, 蔡常春, 张晴, 等. 联合使用大黄、芒硝对重症急性胰腺炎患者肠道功能和炎性因子的影响[J]. 中成药, 2019, 41(5): 1191-1193.
[28]	朱慧, 梁国强, 章一凡, 等. 任氏清胰汤联合西药治疗肝胆湿热型急性胰腺炎的疗效及血清NLRP3、IL-1β、IL-18水平的影响[J]. 四川中医, 2023, 41(6): 126-129.
[29]	张迪, 柳沛林, 孙建飞, 等. 中药治疗重症急性胰腺炎肺损伤机制的研究进展[J]. 中国中医急症, 2024, 33(1): 176-180.
[30]	曹菲, 陈炜炜. 急性胰腺炎中医药治疗的靶点与机制[J]. 中国普外基础与临床杂志, 2024, 31(2): 146-154.
[31]	Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer[J]. Oncotarget, 2017, 8(23): 38022-38043.

组别	例数	年龄(岁,±s)	性别[例(%)]		体重指数(kg/m²,±s)	发病时间(h,±s)	病因[例(%)]
组别	例数	年龄(岁,±s)	男	女	体重指数(kg/m²,±s)	发病时间(h,±s)	胆源性	高血脂	酒精性
对照组	45	41.52±6.70	25(55.56)	20(44.44)	23.52±1.64	8.85±1.25	18(40.00)	17(37.78)	10(22.22)
观察组	45	42.37±7.22	23(51.11)	22(48.89)	23.79±1.77	9.11±1.13	19(42.22)	19(42.22)	7(15.56)
t/χ²		0.579	0.179		0.751	1.035	0.668
P		0.564	0.673		0.455	0.304	0.716

组别	例数	年龄(岁,±s)	性别[例(%)]		体重指数(kg/m²,±s)	发病时间(h,±s)	病因[例(%)]
组别	例数	年龄(岁,±s)	男	女	体重指数(kg/m²,±s)	发病时间(h,±s)	胆源性	高血脂	酒精性
对照组	45	41.52±6.70	25(55.56)	20(44.44)	23.52±1.64	8.85±1.25	18(40.00)	17(37.78)	10(22.22)
观察组	45	42.37±7.22	23(51.11)	22(48.89)	23.79±1.77	9.11±1.13	19(42.22)	19(42.22)	7(15.56)
t/χ²		0.579	0.179		0.751	1.035	0.668
P		0.564	0.673		0.455	0.304	0.716

组别	例数	时间	胸闷腹痛	身热口渴	恶心呕吐	头身沉重	便溏不爽
对照组	45	治疗前	5.31±0.28	5.22±0.25	2.22±0.09	2.14±0.05	2.24±0.08
		治疗后	1.66±0.12^b	1.56±0.15^b	1.11±0.08^b	1.02±0.08^b	0.92±0.07^b
观察组	45	治疗前	5.33±0.25^a	5.18±0.25^a	2.25±0.10^a	2.16±0.07^a	2.22±0.07^a
		治疗后	0.74±0.05^cd	0.68±0.04^cd	0.37±0.10^cd	0.37±0.08^bcd	0.32±0.15^cd
t ^bcd			80.38/120.80/47.47	84.21/119.20/38.03	61.84/89.18/38.76	79.64/113.00/38.54	83.30/77.00/24.32
P^bcd			<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	时间	胸闷腹痛	身热口渴	恶心呕吐	头身沉重	便溏不爽
对照组	45	治疗前	5.31±0.28	5.22±0.25	2.22±0.09	2.14±0.05	2.24±0.08
		治疗后	1.66±0.12^b	1.56±0.15^b	1.11±0.08^b	1.02±0.08^b	0.92±0.07^b
观察组	45	治疗前	5.33±0.25^a	5.18±0.25^a	2.25±0.10^a	2.16±0.07^a	2.22±0.07^a
		治疗后	0.74±0.05^cd	0.68±0.04^cd	0.37±0.10^cd	0.37±0.08^bcd	0.32±0.15^cd
t ^bcd			80.38/120.80/47.47	84.21/119.20/38.03	61.84/89.18/38.76	79.64/113.00/38.54	83.30/77.00/24.32
P^bcd			<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	治愈	显效	有效	无效	治疗总有效率
对照组	45	16(35.55)	8(17.77)	11(24.44)	10(22.22)	35(77.78)
观察组	45	24(53.33)	13(28.88)	6(13.33)	2(4.44)	43(95.56)^a

Please choose a citation manager

Content to export